Cleaning tumor margins via abrogation of heat shock protein 90 with protein engineered tri-block biopolymer-geldanamycin conjugates
- In: SUBMITTED ORALS on Tuesday, 15 April 2014, 13:00-14:30
- At: PSWC, Melbourne (Australia) (2014)
- Type: Presentation
- By: CHEN, Yizhe (University of Utah, Pharmaceutics and Pharmaceutical Chemistry, Salt lake city, United States of America)
- Co-author(s): Youn, Pilju (University of Utah, Salt lake city, United States of America)
Furgeson, Darin (University of Utah, Salt lake city, United States of America)
I. Hepatocellular carcinoma (HCC) remains a lethal cancer with extremely low survival rates. First line clinical therapies, such as thermal ablation, suffer tumor recurrence rates near 40%. Incomplete ablation at tumor margins, poor drug formulation, and lack of drug targeting are suggested as major causes of poor clinical outcomes. Heat shock.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.